0001127602-24-017764.txt : 20240604 0001127602-24-017764.hdr.sgml : 20240604 20240604172724 ACCESSION NUMBER: 0001127602-24-017764 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240531 FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mock James M CENTRAL INDEX KEY: 0001736359 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 241019611 MAIL ADDRESS: STREET 1: 940 WINTER STREET STREET 2: PERKINELMER CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-05-31 0001682852 Moderna, Inc. MRNA 0001736359 Mock James M 325 BINNEY STREET CAMBRIDGE MA 02142 1 Chief Financial Officer 1 Common Stock 2024-05-31 4 M 0 1326 A 7197 D Common Stock 2024-06-03 4 S 0 691 140.7198 D 6506 D Performance Stock Units 2024-05-31 4 A 0 5304 0 A Common Stock 5304 5304 D Performance Stock Units 2024-05-31 4 M 0 1326 0 D Common Stock 1326 3978 D Performance stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025. /s/ James Dillon, As Attorney-in-Fact 2024-06-04